Publications by authors named "Jean Cui"

Claim this Profile
M
Molecular Characteristics of the Uncommon EGFR Exon 21 T854A Mutation and Response to Osimertinib in Patients With Non-Small Cell Lung Cancer.
Lihong Zhang, Xia Yang, Zongjuan Ming, Jie Shi, Xin Lv, Jean Cui

Clin Lung Cancer· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Novel Sequentially Evolved Variant 3 G1202R/S1206Y Double Mutation In Confers Resistance to Lorlatinib: A Brief Report and Literature Review.
Viola W Zhu, Misako Nagasaka, Russell Madison, Alexa B Schrock, Jean Cui

JTO Clin Res Rep· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer.
Mi Ran Yun, Dong Hwi Kim, Seok-Young Kim, Hyeong-Seok Joo, You Won Lee, J Jean Cui

Clin Cancer Res· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum to "Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/G and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib" [Lung Cancer, 108 (June 2017) 228-231].
Sai-Hong Ignatius Ou, Jean Cui, Alexa B Schrock, Michael E Goldberg, Viola W Zhu

Lung Cancer· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Repotrectinib (TPX-0005), effectively reduces growth of ALK driven neuroblastoma cells.
Diana Cervantes-Madrid, Joanna Szydzik, Dan Emil Lind, Marcus Borenäs, Mats Bemark, Jean Cui

Sci Rep· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Osimertinib and dihydroartemisinin: a novel drug combination targeting head and neck squamous cell carcinoma.
Imane Chaib, Xueting Cai, David Llige, Mariacarmela Santarpia, Eloisa Jantus-Lewintre, Jean Cui

Ann Transl Med· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Allosteric, Potent, Subtype Selective, and Peripherally Restricted TrkA Kinase Inhibitors.
Sharan K Bagal, Kiyoyuki Omoto, David C Blakemore, Peter J Bungay, James G Bilsland, J Jean Cui

J Med Chem· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.
Alexander Drilon, Sai-Hong Ignatius Ou, Byoung Chul Cho, Dong-Wan Kim, Jeeyun Lee, J Jean Cui

Cancer Discov· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis.
Niki Karachaliou, Imane Chaib, Andres Felipe Cardona, Jordi Berenguer, Jillian Wilhelmina Paulina Bracht, Jean Cui

EBioMedicine· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of a novel T1151K ALK mutation in a patient with ALK-rearranged NSCLC with prior exposure to crizotinib and ceritinib.
Viola W Zhu, J Jean Cui, Maria Fernandez-Rocha, Alexa B Schrock, Siraj M Ali

Lung Cancer· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib.
Sai-Hong Ignatius Ou, Jean Cui, Alexa B Schrock, Michael E Goldberg, Viola W Zhu

Lung Cancer· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting receptor tyrosine kinase MET in cancer: small molecule inhibitors and clinical progress.
J Jean Cui

J Med Chem· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations.
Ted W Johnson, Paul F Richardson, Simon Bailey, Alexei Brooun, Benjamin J Burke, J Jean Cui

J Med Chem· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A new challenging and promising era of tyrosine kinase inhibitors.
J Jean Cui

ACS Med Chem Lett· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib.
Qinhua Huang, Ted W Johnson, Simon Bailey, Alexei Brooun, Kevin D Bunker, J Jean Cui

J Med Chem· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lessons from (S)-6-(1-(6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)ethyl)quinoline (PF-04254644), an inhibitor of receptor tyrosine kinase c-Met with high protein kinase selectivity but broad phosphodiesterase family inhibition leading to myocardial degeneration in rats.
J Jean Cui, Hong Shen, Michelle Tran-Dubé, Mitchell Nambu, Michele McTigue

J Med Chem· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology.
Sai-Hong Ignatius Ou, Cynthia Huang Bartlett, Mari Mino-Kenudson, Jean Cui, A John Iafrate

Oncologist· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer.
J Jean Cui, Michele McTigue, Mitchell Nambu, Michelle Tran-Dubé, Mason Pairish

J Med Chem· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis of aryl ethers via a sulfonyl transfer reaction.
Neal W Sach, Daniel T Richter, Stephan Cripps, Michelle Tran-Dubé, Huichun Zhu, Jean Cui

Org Lett· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK).
J Jean Cui, Michelle Tran-Dubé, Hong Shen, Mitchell Nambu, Pei-Pei Kung

J Med Chem· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors.
Sergei L Timofeevski, Michele A McTigue, Kevin Ryan, Jean Cui, Helen Y Zou

Biochemistry· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibitors targeting hepatocyte growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases.
Jean Cui

Expert Opin Ther Pat· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a.
Nikolaus Schiering, Stefan Knapp, Marina Marconi, Maria M Flocco, Jean Cui

Proc Natl Acad Sci U S A· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase.
Li Sun, Chris Liang, Sheri Shirazian, Yong Zhou, Todd Miller, Jean Cui

J Med Chem· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rational design of 4,5-disubstituted-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-ones as a novel class of inhibitors of epidermal growth factor receptor (EGF-R) and Her2(p185(erbB)) tyrosine kinases.
Li Sun, Jean Cui, Congxin Liang, Yong Zhou, Asaad Nematalla

Bioorg Med Chem Lett· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis